The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets

Proteomic characterization of human multiple myeloma bone marrow extracellular matrix

(2017) S V Glavey et al.   LEUKEMIA

Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer

(2017) Prasenjit Dey et al.   NATURE

Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia

(2017) Ayuna Hattori et al.   NATURE

The Emerging Hallmarks of Cancer Metabolism

(2016) Natalya N. Pavlova et al.   Cell Metabolism

Meta‐analysis of clinical metabolic profiling studies in cancer: challenges and opportunities

(2016) Jermaine Goveia et al.   EMBO Molecular Medicine

BCAT1, a key prognostic predictor of hepatocellular carcinoma, promotes cell proliferation and induces chemoresistance to cisplatin

(2016) Yi-Hu Zheng et al.   LIVER INTERNATIONAL

Treatment options for relapsed and refractory multiple myeloma

(2015) A. K. Nooka et al.   BLOOD

Smoldering multiple myeloma

(2015) S. V. Rajkumar et al.   BLOOD

Metabolic Signature Identifies Novel Targets for Drug Resistance in Multiple Myeloma

(2015) P. Maiso et al.   CANCER RESEARCH

Missing value imputation strategies for metabolomics data

(2015) Emily Grace Armitage et al.   ELECTROPHORESIS

Multiple myeloma

(2015) Christoph Röllig et al.   LANCET

Saturated and mono-unsaturated lysophosphatidylcholine metabolism in tumour cells: a potential therapeutic target for preventing metastases

(2015) Anna Raynor et al.   Lipids in Health and Disease

Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax

(2015) R Bajpai et al.   ONCOGENE

Glutaminolysis as a target for cancer therapy

(2015) L Jin et al.   ONCOGENE

Alterations in bone marrow metabolism are an early and consistent feature during the development of MGUS and multiple myeloma

(2015) C Ludwig et al.   Blood Cancer Journal

Understanding the role of the kynurenine pathway in human breast cancer immunobiology

(2015) Benjamin Heng et al.   Oncotarget

Targeting the indoleamine 2,3-dioxygenase pathway in cancer

(2015) Yong Wha Moon et al.   Journal for ImmunoTherapy of Cancer

Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

(2014) George C. Prendergast et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Multiple Myeloma Patients Have a Specific Serum Metabolomic Profile That Changes after Achieving Complete Remission

(2013) L. Puchades-Carrasco et al.   CLINICAL CANCER RESEARCH

Glutamate, Glutamate Receptors, and Downstream Signaling Pathways

(2013) Stacey S. Willard et al.   International Journal of Biological Sciences

BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1

(2013) Martje Tönjes et al.   NATURE MEDICINE

Host Indoleamine 2,3-Dioxygenase: Contribution to Systemic Acquired Tumor Tolerance

(2012) Theodore S. Johnson et al.   IMMUNOLOGICAL INVESTIGATIONS

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

(2011) Christiane A. Opitz et al.   NATURE

Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer

(2009) Yuzo Suzuki et al.   LUNG CANCER

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

(2009) M. G. Vander Heiden et al.   SCIENCE

The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology

(2008) A. Curti et al.   BLOOD